Company profile: BrainVectis
1.1 - Company Overview
Company description
- Provider of gene therapies for neurodegenerative and other diseases, aiming to restore brain cholesterol metabolism by increasing CYP46A1 for Huntington’s and Alzheimer’s. Offerings include AB-1005 delivering GDNF to the brain for Parkinson’s, ACT-101 delivering GAA to the liver for Late-Onset Pompe Disease, and NAN-101 activating I-1c to inhibit PP1 for NYHA Class III heart failure.
Products and services
- NAN-101: A cardiac-targeted gene therapy that activates protein phosphatase inhibitor 1 (I-1c) to inhibit PP1, aiming to improve heart function in NYHA Class III heart failure
- ACT-101: A liver-directed gene therapy engineered to deliver a functioning GAA gene copy to the liver for Late-Onset Pompe Disease, potentially eliminating chronic enzyme replacement therapy requirements
- AB-1005: A brain-delivered gene therapy that administers the GDNF gene directly to the brain to restore dopamine levels in patients with Parkinson’s disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BrainVectis
ReadCoor
HQ: United States
Website
- Description: Provider of the first true spatial multi-omic platform (RC2) that simultaneously detects and reads sequences, serving a global audience of researchers, clinicians, pharma and diagnostics companies to expand understanding of human biology and facilitate the creation of new therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReadCoor company profile →
Instant Labs
HQ: United States
Website
- Description: Provider of a fully-integrated, portable, and affordable real-time polymerase chain reaction (RT-PCR) platform for rapid, accurate pathogen detection, developing and marketing the Hunter Real-Time-PCR system. Focus areas include molecular diagnostic equipment, food safety testing equipment, and food verification testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Instant Labs company profile →
Tune Therapeutics
HQ: United States
Website
- Description: Provider of an epigenetic programming platform for disease treatment, offering TEMPO to control gene activity without altering DNA sequence by activating, silencing, or fine-tuning gene output, and TUNE-401, an investigational HBV therapy that epigenetically silences viral DNA in host chromosomes and cccDNA to pursue a functional cure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tune Therapeutics company profile →
MultiVir
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies, including investigational Ad-p53 and Ad-IL24 tumor suppressor immune gene therapies delivering normal genes into tumors to restore suppressor functions and stimulate anti-tumor responses; an Ad-p53 dendritic cell therapeutic vaccine; and combination regimens with anti-PD-1/PD-L1 for recurrent/metastatic cancers and advanced melanoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MultiVir company profile →
Orna Therapeutics
HQ: United States
Website
- Description: Provider of engineered circular RNA therapeutics and tools: isCAR therapy using oRNA and proprietary LNPs to modify immune cells for tumor control without lymphodepletion; oRNA-based dystrophin replacement via non-viral delivery to liver and muscle; next-generation vaccines with Merck using oRNA/LNP; and FoRCE for high-throughput oRNA sequence evaluation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BrainVectis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BrainVectis
2.2 - Growth funds investing in similar companies to BrainVectis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BrainVectis
4.2 - Public trading comparable groups for BrainVectis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →